67 filings
8-K
CNSP
Cns Pharmaceuticals Inc
7 May 24
Other Events
5:00pm
8-K
CNSP
Cns Pharmaceuticals Inc
3 May 24
Departure of Directors or Certain Officers
4:26pm
8-K
CNSP
Cns Pharmaceuticals Inc
12 Apr 24
Regulation FD Disclosure
6:37pm
8-K
CNSP
Cns Pharmaceuticals Inc
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
8-K
CNSP
Cns Pharmaceuticals Inc
27 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
q98w1de7
21 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
zfim6j k3
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
6rnry9buebr
23 Jan 24
Departure of Directors or Certain Officers
4:01pm
8-K
gu1dez5c6vf1 bxi
21 Dec 23
Regulation FD Disclosure
9:15am
8-K
zis4zyi8nb7zs2v9hr5
18 Dec 23
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy
8:36am
8-K
ziggch2d 754m714w
15 Nov 23
Results of Operations and Financial Condition
8:00am
8-K
51dtbmb
18 Oct 23
Regulation FD Disclosure
9:00am
8-K
w5kkpdsbzryks4nm 55
17 Oct 23
Entry into a Material Definitive Agreement
8:00am
8-K
2uf5n2bm
18 Sep 23
Submission of Matters to a Vote of Security Holders
7:51pm
8-K
g9cvrim8tqvtynt9y
18 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
3zf75u22djwpbgaa 5tj
15 Aug 23
Amendments to Articles of Incorporation or Bylaws
8:30am
8-K
pore auqyy65zbc2tt
14 Aug 23
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Continued rapid pace of enrollment with ~75% of expected patients now enrolled
9:25am
8-K
3ubbjzs8c hq134au
15 May 23
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides
8:36am
8-K
5rvs44j9
8 May 23
Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
8:45am
8-K
qsph yic8
3 Jan 23
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors
8:45am